Evolus partners with IBSA to launch Profhilo in the U.S.
Evolus entered a deal with IBSA to license Profhilo, a leading European skin quality injectable. This allows the company to expand its portfolio into the fast-growing U.S. aesthetic market.
View filing at SEC.gov →